Try our Advanced Search for more refined results
Life Sciences - May, 2013
275 articles
- FCPA Powerhouse: Debevoise
- Settlement Approved In Cold Remedy False Ad Suit
- Avanir Sues Sandoz Over Nuedexta Generic
- Tolling Approved In Bayer $100M Sex Bias Suit
- Battle For K-V Pharma Amps Up As Silver Point Boosts Offer
- Judge's Alcon Dismissal Ends Drug Kickback Qui Tam Suit
- Shire, Teva Call Truce In Fight Over Generic ADHD Drug
- State, Federal NECC Tort Cases To Join Meningitis MDL
- Boston Scientific Unit Can't Duck FCA Claims, DQ Blank Rome
- FDA Rejects Endo Testosterone Drug For 3rd Time
- EU Agency Warns Of GSK Epilepsy Drug's Vision Risks
- Baxter Relators Can't Reopen $30M Price Inflation Suit
- Medicare's Future Depends On Health Co. Squeeze: Trustees
- Schering Says FCA Integrilin Kickbacks Suit Doesn't Stick
- Courts Unswayed By Protests Over AG Outside Counsel Hires
- ArthroCare Exec Pleads Not Guilty In $400M Fraud Scheme
- Device Cos. Slam FDA's Overseas Clinical Trial Rule
- Intema Seeks High Court Review Of Nixed Fetal Test Patent
- Merck Investors Can't Use Vioxx News Report In Fraud MDL
- Biotech Firms, Exec Pay $11M To Settle NJ Fraud Suit
- Procurement: The Hidden Path To Maximizing Profits
- FCPA Powerhouse: Davis Polk
- Takeda Sues 3 Rivals Over Planned Heartburn Drug Generics
- Hospira Told To Clean Up Manufacturing Process In India
- NZ's Ebos Inks $888M Deal For Aussie Drug Wholesaler
- K-V Investor Group Bumps Up Ch. 11 Offer To $275M
- Doryx Antitrust Class Cert. Bids Fall Short, Warner Says
- 9th Circ. Ruling Threatens Shoddy Medicare Part D Insurers
- J&J Unit Cleared Of Union's Info Withholding Charges
- 10th Circ. Reverses Zimmer Win In Knee-Implant Injury Suit
- Eli Lilly Sues Perrigo To Block Generic Testosterone Drug
- Bankrupt K-V Settles Texas Medicaid Fraud Suit For $3M Claim
- Amphastar Asks Justices Not To Review Drug Safe Harbor
- And Now A Word From The Panel ...
- Stryker Looks For Quick Coverage Win In Knee Deal Row
- GSK Pays $321M For Swiss Vaccine Developer Okairos
- ArthroCare Exec Wants Conspirators' Names In $400M Fraud
- J&J Unit Can't Stop Ex-Sales Reps From Working For Rival
- FCPA Powerhouse: Crowell & Moring
- Good Faith Clauses Not Just For Show: Del. Supreme Court
- Rotech Shareholders Seek To Undo $30M DIP Order
- FDA Blasted Over Shared Risk Plans For Brand, Generic Cos.
- Merck Loses Bid To Block Outside Attys In Ky. Vioxx Case
- NJ High Court Agrees To Consolidate Bayer's Mirena Cases
- 9th Circ. Backs Class Cert. In Medline Workers' Wage Suit
- Sergeant's Flea-Killer Ads Blocked In Bayer False Ad Suit
- Shire Division Head Says Firm Duped Him Into Taking Job
- AstraZeneca Spends $443M On Lipid Drug Specialist
- FDA Urges Strong Quality Pacts For Drugmakers, Contractors
- Plan B Advocates Don't Grasp FDA Process, 2nd Circ. Told
- FCPA Powerhouse: Cahill Gordon & Reindel
- Bad Birth Control Packaging Led To Pregnancy, Suit Says
- Valeant Puts Up $8.7B For PE-Backed Bausch & Lomb
- A Look At The Patentability Of 3-D Printed Human Organs
- Fed. Circ. Blocks Generic Sales Of AstraZeneca's Pulmicort
- Conceptus Investor Can't Block $1.2B Bayer Acquisition
- Primcogent Files Ch. 11 In Feud With Fat-Zapping Laser Maker
- Lupin Must Produce Generic Info In Warner Chilcott Suit
- JPML Head Judge Explains Why Panel Is More Picky
- 1st Circ. Revives CVS Shareholder Fraud Class Action
- B&L Unit To Pay $34M For Drug Marketing Guilty Plea: DOJ
- Arbitration Bias Claim In Drug Row Premature, Judge Says
- Law360 Names 10 FCPA Powerhouse Firms
- Fresenius Hits Dr. Reddy's With Diprivan IP Suit
- Royalty Gets 68K Shares Of Support For $6.3B Elan Takeover
- Intuitive Not Negligent In Surgery Death, Jury Rules
- USPTO's Patent Term View Oversteps Authority, Drug Co. Says
- Flonase Users Seek Sanctions For Foes Of $35M Antitrust Deal
- DePuy Loses Bid To Toss $8.3M Hip Implant Verdict
- Ex-Smith & Nephew Exec Loses Sanctions Bid In FCA Suit
- Capsule Seller Can't Duck Suit Over Testosterone Claims
- Forest Labs Subpoenaed Over New COPD Inhaler
- Deals Rumor Mill: Valeant, Google, Suntory
- You May Be Liable For Someone Else's Overintoxication
- Vaccine Distributor Antitrust Claims Should Stick, Judge Told
- Watson, Apotex Settle Azilect Patent Infringement Suit
- Cigna Gets Heart Device Coverage Fight Sent To Arbitration
- Ex-Pfizer Counsel Tapped For NJ County Prosecutor Job
- Deals Sizzle, BBQs To Follow For Busy Deal Makers
- FDA Bans Certain Imports From Indian Drugmaker Wockhardt
- Daiichi Sankyo Mulls Legal Action Over Ranbaxy Settlements
- 6th Circuit Takes Wide View Of Liability In Stock Inflation Suits
- How Monsanto Applies To Nonagricultural Biotechnology
- Kramer Settles Fungi-Nail False Ad Suit
- Royalty Pharma Revises Conditions Of $6B Elan Takeover
- Ex-Watson Manager Says Homophobia Concerns Led To Firing
- FDA Panel Clears Merck Insomnia Drug At Lower Dose
- FDA Shows Deft Touch With 1st Mobile App Enforcement
- Test Strip Maker Barred From Using J&J Unit's Logo In Ads
- Fen-Phen User Fairly Denied Extra Benefits, 3rd Circ. Finds
- Pfizer Plans Stock Swap To Exit Thriving Animal Health Biz
- Senate Panel Advances Drug Compounder Oversight Bill
- Nobel To Pay $1.3M To Settle Faulty Implant Suit
- GSK Awarded Up To $200M For Bioterror Drug Program
- The Starstruck Medical Causation Trend
- Biotech Exec Indicted On Charges He Stole Investor Funds
- Novo To Lay Down $700M For Antibiotics Specialist Xellia
- Herbalife Preys On Latinos, Nonprofit Tells FTC
- Jury Convicts Atty Over Stock Fraud Scheme With Ex-NFLer
- Herbalife Taps PwC As Auditor After KPMG Insider Scandal
- Whistleblower Takes Takeda FCA Case To Supreme Court
- Boehringer, Hospira Products Adulterated, FDA Warns
- Deals Rumor Mill: Dish, Alere, Raytheon
- Reps. Urge Delay Of Medicare Competitive Bidding Program
- Judge Disqualifies Whistleblowers' Attys In Kinetic FCA Suit
- Digging Into The Duty To Mine Big Data
- Pfizer Can't Shake Skelaxin Pay-For-Delay MDL
- High Court Could Put Patent Burden Of Proof On Licensees
- Fighting Agencies May Be Tougher After High Court Ruling
- High Court's Atty Fee Ruling May Spur More Vaccine Claims
- Plan B Ruling Shouldn't Be Stayed, 2nd Circ. Told
- FDA Airs Safety Concerns About Merck Insomnia Drug
- Fed. Circ. Revives 5 Mylan Drug Patents In Sunovion Row
- Fed. Circ. Flips Noninfringement Judgment In Allegra IP Row
- Agencies Deserve Deference On Jurisdiction, Justices Say
- Zydus Defends Obvious Challenge In Zegerid Patent Row
- Dental-Care Company Infringes Crest Patents, P&G Says
- Royalty Pharma Ups Hostile Bid To $6.3B As Elan Maneuvers
- Omnicare Gets FCA Off-Label Prescription Action Trimmed
- High Court Takes Up Medtronic Patent Burden Of Proof Case
- Actavis Puts Up $8.5B For Warner Chilcott
- High Court Takes On Declaratory Judgment Burden Of Proof
- Hedge Fund Sues For Proxy Fight Rematch With Digirad
- MLB Suit Over Performance Boosters Falls Flat, Clinic Says
- Drug Co. Scores Partial Win In Suit Over Botched Offering
- Criminal Probes Await Top Health Cos.: Ex-DOJ Fraud Chief
- AbbVie Targets Hetero Over Generic Norvir Plans
- Pa. Appeals Court To Reconsider $28M Knee Injury Suit
- Rise Of The Machines — Predictive Coding Goes Mainstream
- Obama Budget Would Save $153B In Health Spending: CBO
- Galderma Settles Pimple Drug Patent Suit With Par
- House Dems Seek Tougher Drug Trial Reporting Rules
- European Panel OKs Bayer Acne Drug For Some Women
- FDA Details Approach To Expedited Medical Device Reviews
- GSK Says Comcast Ruling Kills Avandia Injury Class Action
- Steptoe Nabs Trio Of Patent Litigators For Chicago Office
- Allergan Targets Strides, Agila Over Generic Eye Drops
- The Growing Problem Of Fishy Labeling
- J&J To Stop Selling Metal Hips, Facing Thousands Of Suits
- Purdue Puts Generic OxyContin Suits To Rest
- 5 Steps To Take Now For A Successful Recall Later
- J&J Unit Wants Ban On Rival's Use of IP, Logos in Ads
- Axiom Wins Sanctions In Medical Device Trademark Row
- Medical Supplier BestMed Dodges $3.5M Verdict In IP Row
- Athena Blasts Allergan's Competition Claims In Eyelash Fight
- Harvard Can't Reverse USPTO On Mouse-Testing Patent
- Endo Claims Teva, Others Infringe Uncrushable Opana IP
- FDA Details Appeals Process For Rejected Medical Devices
- J&J's S. Korean Unit Faces Charges After Tylenol Recall
- J&J Units Sued Over Spine Implant Patent
- Biolitec Wants Judge Booted In AngioDynamics Row
- Panel Sends Drug-Tracking Bill To House Floor
- FDA Needs To Revamp Benefit-Risk Analysis, Drugmakers Say
- Obama's 1st Term Rulemaking Rate Soars By Bush's Mark
- Lawmakers Forge Ahead On Drug Compounder Oversight Bill
- CMS Sued Over Medicare Prosthetics Payment Rule
- FDA Eases Up On 'Smart Pills' For Wireless Monitoring
- Mass Tort For Tylenol Liver Injuries Requested In NJ
- Rotech Bondholders Want Baker & McKenzie Fees Capped
- Bayer Hits Par With Patent Suit Over Staxyn Generic
- FDA Tells DC Circ. KV Drug Compounding Wasn't A Priority
- Dissident Quigley Creditors Now Support Ch. 11 Plan
- Novartis Wins Jury Verdict Over Zometa's Bone Death Risk
- K-V Case Tests Limits Of ITC Jurisdiction
- 9th Circ. OKs Revoking Medicare Part D Insurer's Contract
- Suit Over Novartis Drug's Bone Death Risk Heads To Jury
- FDA Approves Lower Doses For Sleep Aids
- 3M Infringes Self-Sticking Bandage Patent, Suit Alleges
- Boston Scientific's UK Arm Hit With German Stent Sale Ban
- Genzyme Investors Urge 1st Circ. To Revive Fraud Action
- Pain Patch Maker Wins Coverage Of False Ad Suit
- 2nd Circ. Upholds Standard For SEC Debarment Of Officers
- Sanofi Fined $53M In France Over Generic Plavix Smears
- Shook Hardy Lands Stradley Ronon Life Sciences Whiz
- Get Ready For Stricter RMP Enforcement
- Kasowitz Lures Fish & Richardson IP Atty In Silicon Valley
- AstraZeneca Sues Actavis Over Planned Generic Vimovo
- NJ Court Won't Revive Sun Pharma's Contract Breach Suit
- CR Bard Pays $48M To Settle FCA, Kickback Claims
- CVS, Cardinal Health Returned Opened Drugs, Savient Says
- Teva Defends IP Suit Over Generic MS Drug Research
- Novartis Tells High Court State Punitive Awards Are Illegal
- AGs Urge FDA To Warn Of Newborn Opioid Withdrawal
- Thermo Fisher Hid Mexico Plant's Cartel Woes, OpenGate Says
- Nobel Biocare $1.3M Dental Impact Settlement Stalls
- Ranbaxy Pays Record $500M To End Tainted Drug Claims
- Vitamin C Classes Blast Bid To Nix $153M Antitrust Verdict
- Fired Exec Says Research Firm Illegally Tracked Applicants
- Elan's $1B Royalty Buy Beefs Up Hostile Takeover Defense
- Actavis, Warner Chilcott In Merger Talks
- Drug Cos. See Path To Legal Off-Label Marketing
- Star Scientific Shareholders Sue Over Drug Claims
- Teva Pushes Fed. Circ. To Revive Seasonique Patent Suit
- Robotic Surgery Part May Burn Patients, Intuitive Warns
- Genentech Patent Win Can't Halt Foreign Arbitration
- NECC Dodged Patient-Specific Compounding Rule, Docs Say
- Aveo Hid Kidney Drug's Higher Death Risk, Shareholder Says
- NY Judge Rejects Delay Of Wider Plan B Access
- Novartis Expert Denies Zometa Caused Bone Death In NJ Trial
- LCD Cases May Give Drug Cos. Gold Ticket Out Of State Court
- Arthrocare Exec Cops To $400M Securities Fraud Scheme
- Lawmakers Press Supplement Cos. About DMAA Sales
- Abbott, AbbVie Hit With $2.2M Verdict In Humira Suit
- Allergan Asks Fed. Circ. To Revive Pinkeye Patent Suit
- Shire Blocks Actavis' Generic Lialda Until 2020
- Device Co. Didn't Infringe UV Sterilization Patents, Judge Says
- Compounder Oversight Bill Needs Tweaks, FDA Official Says
- Merck's 'Boys Club' Targeted In $100M Gender Bias Suit
- B. Braun Faces Patent Suit Over Medical Infusion Devices
- Seyfarth Shaw Atty Ducks Sanctions For Missed Conference
- Dissecting The Rules Of Generic Drug User Fee Amendments
- E-Discovery In The Cloud: Who Can Get Your Data?
- Celgene Loses Sanctions Bid Against Teva Unit In Patent Row
- House Panel Approves Prescription Drug Tracking Bill
- K-V Pharma Gets More Time To Hammer Out Ch. 11 Plan
- Bill Would Put Squeeze On FDA Over Antibiotic Resistance
- Abbott, AbbVie Should Pay $5.8M In Humira Suit, Jury Told
- AbbVie, Teva Pay-For-Delay Deal Draws More Antitrust Claims
- ArthroCare Faces DOJ Investigation Over Billing Practices
- 5 Reasons For Optimism In The Venture Capital Community
- Deals Rumor Mill: Sprint, Bain Capital, Bankia
- Icahn Boosts Herbalife Stake Amid Battle For Co.'s Future
- Bristol-Myers Seeks To Bust Genentech Cancer Drug Patents
- Mannatech Sytematically Ousted Female Execs, Ex-VP Says
- CoreValve Asks High Court To Define Patent Enablement
- Canadian Health Officials Hushed Drug Research, Suit Says
- Minn. Appeals Court Revives Drug Overcharge Class Action
- Jones Day Nabs Former Greenberg Life Sciences Litigator
- Judge Slams HHS Over Plan B 'Administrative Filibuster'
- Alcon Urges Dismissal Of Drug Bottle Size Class Action
- Whistleblowers Say DaVita Abusing Doc Privilege In FCA Case
- Preparing A Successful Daubert Motion
- Lessons From Philips FCPA Settlement Over Polish Bribes
- Plan B Ruling's Supporters Urge Judge To Reject Stay
- Stryker, Smith & Nephew Sued Over Bone Plate Patent
- CVS Stops Some Prescription Reminders, Citing HIPAA Update
- Jury Finds Cellectis Patent Claims Against Rival Invalid
- Biomet Accused Of Breaking Patent Deal
- Humira Risks Were Known Before Abbott Letter, Doc Says
- Cancer Drug Kadcyla Must Be Called By Full Name, FDA Says
- Vitacost Beats Suit Over Pre-IPO Disclosures In 11th Circ.
- Punitive Damage Claims Kept Alive In NuvaRing Bellwethers
- Chum Of Ex-Orioles Player Dodges Insider Trading Charges
- Abbott Followed FDA Rules On Humira Updates, Jury Hears
- Ex-Frontier Chemist Dodges Prison For Disclosing Recipes
- Illumina Fails To Shred Syntrix DNA Patent After $96M Verdict
- Kilpatrick Lures Medical IP Vet Back From Industry Role
- 11th Circ. Denies Cert. Appeal In $867M Astellas Antitrust Suit
- K-V Pharma Will Pursue Investors' Alternative Ch. 11 Plan
- FDA Stings Gilead For Manufacturing Violations
- CORRECTED: Judge Pads Stryker's $4.5M Interest Award In Knee Suit
- Pfizer Unit Beats RICO Claims In Skelaxin Pay-For-Delay Row
- Novartis Safety Efforts Challenged In NJ Zometa Trial
- Pharma Cos. Smell Victory In Push For Drug-Tracking System
- Mintz Levin Adds Goodwin IP Atty, WilmerHale Securities Pro
- Apotex's Planned Angiomax Generic Spurs Patent Suit
- Biotech King Gets 4 Years For Stock Manipulation
- Royalty Will Go No Higher In Bid For Elan, Citing J&J Sell-Off
- Fed. Circ. Upholds Most Patents For Allergan Glaucoma Drug
- Pa. Can't Hog Fee Award From Vioxx Settlement, Judge Says
- Appriva Investors Win $250M Jury Award In Contract Fight
- Feds Will Appeal Ruling On Morning-After Pill
- Takeda Ditches $6M Award Linking Diabetes Drug To Cancer
- Novartis Stresses FDA Approvals In Zometa Trial
- Pharma Co. Sues K&L Gates Over Bungled Stock Offering
- High Court Asked To Review 2nd Circ. Fosamax Ruling
- Medicare Board Won't Be Triggered Until 2015, Expert Says
- KV Pharma Can't Duck Securities Suit Over FDA Woes
- Kinetic Wants To DQ Whistleblowers' Attys Over Misused Docs
- NuVasive, Biosystems Settle Noncompete Dispute
- FDA Ignores Toxic Arsenic In Animal Feed, Suit Says
- Generics Co. Rips Novartis' Bid To Combine Reclast Suits
- AbbVie, Teva Hit With 2 More Niaspan Pay-For-Delay Suits
- Deals Rumor Mill: Yahoo, Bain Capital, Fin
- How HIPAA Marketing And Sale Provisions May Apply To You